CD8A and neoplasm: After a series of multidisciplinary treatment discussions focusing on the maintenance of postoperative antitumor therapy and sufficient informed consent, all patients continued using the PD-1 inhibitor for at least 6 months for the following reasons: as the body’s antitumor immunity is activated, participants in antitumor immunity, such as CD8+ T cells, tumor-associated macrophages (TAMs), and natural killer (NK) cells, exist not only in the tumor immune microenvironment but also in peripheral circulating blood.